W R J Taylor
Affiliation: World Health Organization
- Malaria and the lungW R J Taylor
World Health Organization TDR, Avenue Appia 20, Geneva 27, CH 1211, Switzerland
Clin Chest Med 23:457-68. 2002..More research is needed to better define and tailor treatments for malarial and nonmalarial ALI and ARDS...
- Assessing the Parasight-F test in northeastern Papua, Indonesia, an area of mixed Plasmodium falciparum and Plasmodium vivax transmissionWalter R J Taylor
US Naval Medical Research Unit No 2, Jakarta, Indonesia
Am J Trop Med Hyg 66:649-52. 2002..falciparum parasitemia in patients presenting with clinical malaria. However, the high false-positive rate on day 7 limits its use for patient follow-up...
- Tolerability of azithromycin as malaria prophylaxis in adults in northeast papua, indonesiaWalter R Taylor
U S Naval Medical Research Unit No 2, National Institutes of Health, Jakarta, Indonesia
Antimicrob Agents Chemother 47:2199-203. 2003..One azithromycin recipient developed an erythematous rash. Daily azithromycin was well tolerated by these Indonesian adults during 20 weeks of treatment...
- Antimalarial drug toxicity: a reviewW Robert J Taylor
WHO Tropical Disease Research, Geneva, Switzerland
Drug Saf 27:25-61. 2004..Combining an artemisinin derivative with another efficacious antimalarial drug is increasingly being viewed as the optimal therapeutic strategy for malaria...
- Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in UgandaFrancesco Checchi
Epicentre, Paris, France
Malar J 5:59. 2006....
- Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in ColombiaLyda Osorio
Internacional Centre for Medical Research and Training CIDEIM Avenida 1N 3 03, Cali, Colombia
Malar J 6:25. 2007..Artemisinin-based combination therapy (ACT) is being widely promoted as a strategy to counteract the increase in Plasmodium falciparum antimalarial drug resistance...
- Molecular genotyping in a malaria treatment trial in Uganda - unexpected high rate of new infections within 2 weeks after treatmentKefas Mugittu
Ifakara Health Research and Development Centre, Ifakara, Tanzania
Trop Med Int Health 12:219-23. 2007..2%)] and 14 [24/51 (47.1%)]. These results impact significantly on resistance monitoring and point to the value of genotyping all recurrent infections in antimalarial trials...
- Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitroMonica Longo
Department of Preclinical Development, Nerviano Medical Sciences S r l, Viale Pasteur 10, 20014 Nerviano, Milan, Italy
Reprod Toxicol 21:83-93. 2006..Extrapolating results to pregnant women exposed in the first trimester remains difficult. Pharmacovigilance and further studies of the mechanism of damage are needed...
- In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-upKasia Stepniewska
Faculty of Tropical Medicine, Mahidol University, 420 6 Rajvithi Rd, Bangkok 10400, Thailand
Antimicrob Agents Chemother 48:4271-80. 2004..94) or if the entomological inoculation rate was known. In the assessment of drug efficacy against falciparum malaria, 28 days should be the minimum period of follow-up...
- Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trialCharles O Obonyo
Centre for Vector Biology and Control, Kenya Medical Research Institute, Kisumu, Kenya
Trans R Soc Trop Med Hyg 97:585-91. 2003..However, the high background rate of parasitological failure with SP may make this combination unsuitable for widespread use in Kenya...
- Efficacy of artesunate plus chloroquine for the treatment of uncomplicated malaria in children in Burkina Faso: a double-blind, randomized, controlled trialSodiomon Bienvenu Sirima
Centre National de Recherche et de Formation sur le Paludisme, Ministere de la Sante, 01 B P 2028, Ouagadougou 01, Burkina Faso
Trans R Soc Trop Med Hyg 97:345-9. 2003..Despite the beneficial effects of adding AS, the high failure rate at day 28 of CQ-AS precludes its use as the first-line regimen for treating CQ-resistant P. falciparum in Burkina Faso...
- Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: a randomized, double-blind, placebo-controlled trialGerardo Priotto
Epicentre, 8 rue Saint Sabin, 75011 Paris, France
Trans R Soc Trop Med Hyg 97:325-30. 2003..Treatment efficacy improved with SPAS3 but the cure rate at day 28 was modest. The combinations were well tolerated and safe. In areas where SP resistance is prevalent other combinations should be considered...
- Short report: in vivo sensitivity of Plasmodium falciparum to halofantrine in southern central VietnamHanh Nhan Doan
U S Naval Medical Research Unit No 2, Jakarta, Indonesia
Am J Trop Med Hyg 69:553-4. 2003..8-99.2%) patients were sensitive. Two patients had recurrent P. falciparum parasitemia on days 14 and 21. Halofantrine effectively treated uncomplicated P. falciparum malaria in these Vietnamese patients...
- Antimalarial compounds: from bench to bedsidePiero L Olliaro
UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
J Exp Biol 206:3753-9. 2003..This review will summarise current antimalarial drug developments and outline recent clinical research that aims to bring artemisinin-based combinations to those that need them most...
- Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern SénégalPhilippe Brasseur
UR 077, IRD, Dakar, Senegal
Malar J 6:150. 2007..There are no data on the long term use of an artemisinin combination treatment in moderate or high transmission areas of Africa...